Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Duvivier

Showing results (391-400 of 505) with videos related to

Pageof 51
Sort By:
Infectious Diseases (London, England)|January 14, 2016
Long-term efficacy and safety of etravirine-containing regimens in a real-life cohort of treatment-experienced HIV-1-infected patientsClotilde Allavena, Christine Katlama, Laurent Cotte, et al.
Journal of the International AIDS Society|November 15, 2014
Efficacy and tolerability of Etravirine in HIV-1 adult patients: Results of a large French prospective cohortClotilde Allavena, Christine Katlama, Laurent Cotte, et al.
Plos One|October 22, 2015
Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected PatientsIsabelle Poizot-Martin, Alissa Naqvi, Véronique Obry-Roguet, et al.
Journal of Medical Virology|October 2, 2012
Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1Jade Ghosn, Laurence Slama, Aziza Chermak, et al.
The Journal of Antimicrobial Chemotherapy|October 15, 2021
Dolutegravir-based dual maintenance regimens combined with lamivudine/emtricitabine or rilpivirine: risk of virological failure in a real-life settingColin Deschanvres, Jacques Reynes, Isabelle Lamaury, et al.
European Journal of Pharmacology|October 13, 2025
Asparagine synthetase promoter hypermethylation is required, but not sufficient, for sensitivity to Asparlas in patient-derived models of hepatocellular carcinomaEthika Tyagi, Magdalena Pohorecka, Damien Valour, et al.
Plos One|February 3, 2017
Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy - Results from a large french multicenter cohort studyLaurent Cotte, Tristan Ferry, Pascal Pugliese, et al.
Medecine Et Maladies Infectieuses|September 6, 2005
[The Nadis cohort: 6236 HIV-infected patients followed up in French university hospitals]R Agher, C Duvivier, C Katlama, et al.
AIDS (London, England)|August 31, 2010
Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136Christine Katlama, Marc A Valantin, Michele Algarte-Genin, et al.
Transplant Immunology|September 24, 2004
Transplantation of islets transduced with CTLA4-Ig and TGFbeta using adenovirus and lentivirus vectorsJustin R Fernandes, Valérie F Duvivier-Kali, Mitchell Keegan, et al.
Pageof 51

Showing results (391-400 of 505) with videos related to

Sort By:
Pageof 51
Infectious Diseases (London, England)|January 14, 2016
Long-term efficacy and safety of etravirine-containing regimens in a real-life cohort of treatment-experienced HIV-1-infected patientsClotilde Allavena, Christine Katlama, Laurent Cotte, et al.
Journal of the International AIDS Society|November 15, 2014
Efficacy and tolerability of Etravirine in HIV-1 adult patients: Results of a large French prospective cohortClotilde Allavena, Christine Katlama, Laurent Cotte, et al.
Plos One|October 22, 2015
Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected PatientsIsabelle Poizot-Martin, Alissa Naqvi, Véronique Obry-Roguet, et al.
Journal of Medical Virology|October 2, 2012
Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1Jade Ghosn, Laurence Slama, Aziza Chermak, et al.
The Journal of Antimicrobial Chemotherapy|October 15, 2021
Dolutegravir-based dual maintenance regimens combined with lamivudine/emtricitabine or rilpivirine: risk of virological failure in a real-life settingColin Deschanvres, Jacques Reynes, Isabelle Lamaury, et al.
European Journal of Pharmacology|October 13, 2025
Asparagine synthetase promoter hypermethylation is required, but not sufficient, for sensitivity to Asparlas in patient-derived models of hepatocellular carcinomaEthika Tyagi, Magdalena Pohorecka, Damien Valour, et al.
Plos One|February 3, 2017
Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy - Results from a large french multicenter cohort studyLaurent Cotte, Tristan Ferry, Pascal Pugliese, et al.
Medecine Et Maladies Infectieuses|September 6, 2005
[The Nadis cohort: 6236 HIV-infected patients followed up in French university hospitals]R Agher, C Duvivier, C Katlama, et al.
AIDS (London, England)|August 31, 2010
Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136Christine Katlama, Marc A Valantin, Michele Algarte-Genin, et al.
Transplant Immunology|September 24, 2004
Transplantation of islets transduced with CTLA4-Ig and TGFbeta using adenovirus and lentivirus vectorsJustin R Fernandes, Valérie F Duvivier-Kali, Mitchell Keegan, et al.
Pageof 51